International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	GUANFACINE IN THE TREATMENT OF ATTENTION – DEFICIT/HYPERACTIVITY DISORDER: MECHANISMS, CLINICAL EVIDENCE AND THERAPEUTIC IMPLICATIONS
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5501
RECEIVED	01 March 2026
ACCEPTED	07 June 2026
PUBLISHED	19 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

GUANFACINE IN THE TREATMENT OF ATTENTION – DEFICIT/HYPERACTIVITY DISORDER: MECHANISMS, CLINICAL EVIDENCE AND THERAPEUTIC IMPLICATIONS

Natalia Kita *(Corresponding Author, Email: nataliakita@poczta.onet.pl)*
University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0001-2277-6198

Patrycja Broniszewska
University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0000-6577-307X

Marta Kamrowska
University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0001-1570-0144

Jakub Świech
University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0001-1732-4162

Filip Kopacki
University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0005-7897-8222

Katarzyna Apanasewicz
J. Strus Multidisciplinary Municipal Hospital in Poznań, Poland
ORCID ID: 0009-0001-0765-5398

Weronika Szczeblewska
Independent Public Provincial Integrated Hospital in Szczecin, Poland
ORCID ID: 0009-0007-3956-622X

Daniel Jaskot
Independent Public Provincial Integrated Hospital in Szczecin, Poland
ORCID ID: 0009-0004-8678-9838

Jakub Marzec
University Clinical Hospital No. 1, Pomeranian Medical University in Szczecin, Poland
ORCID ID: 0009-0007-8336-7260

Natalia Sztenc
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0006-4307-7958

ABSTRACT

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition associated with persistent impairments in attention and executive functioning. Although psychostimulants remain the most effective pharmacological treatment, not all patients tolerate them well, and a considerable proportion shows only partial response. For this reason, interest in non-stimulant medications, including guanfacine, has grown in recent years.

Guanfacine, a selective α2A-adrenergic receptor agonist, primarily acts on prefrontal cortical networks involved in cognitive control. This review summarizes current evidence on its mechanism of action, clinical efficacy, and safety profile. Overall, available data indicate that guanfacine provides clinically meaningful benefits—particularly in pediatric populations and as adjunctive therapy—although its effect size is generally smaller than that of psychostimulants. Nevertheless, due to its favorable tolerability and distinct pharmacological profile, it represents a useful option within individualized treatment strategies.

KEYWORDS

ADHD, Guanfacine, Alpha-2 Agonists, Prefrontal Cortex, Non-Stimulant Treatment

CITATION

Natalia Kita, Patrycja Broniszewska, Marta Kamrowska, Jakub Świech, Filip Kopacki, Katarzyna Apanasewicz, Weronika Szczeblewska, Daniel Jaskot, Jakub Marzec, Natalia Sztenc. (2026) Guanfacine in the Treatment of Attention–Deficit/Hyperactivity Disorder: Mechanisms, Clinical Evidence and Therapeutic Implications. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5501

1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is among the most frequently diagnosed neurodevelopmental disorders, with prevalence estimates remaining relatively stable across decades (Polanczyk et al., 2014). While it has long been considered primarily a childhood condition, it is now well established that symptoms often persist into adulthood, although their clinical presentation may change over time (Simon et al., 2009; Sibley et al., 2016).

Beyond its core symptoms, ADHD significantly affects academic achievement, occupational functioning, and interpersonal relationships (Kessler et al., 2006). In addition, it contributes to broader societal burden, including increased healthcare utilization and reduced productivity. Therefore, effective and well-tolerated treatment strategies remain an important clinical and public health priority.

Psychostimulants are currently regarded as the most effective pharmacological treatment. However, their use may be limited by adverse effects, contraindications, or insufficient response in some patients (Cortese et al., 2018). As a result, non-stimulant options have gained increasing attention. Among these, guanfacine represents a clinically relevant alternative with a distinct mechanism of action.

2. Neurobiological Basis of ADHD

Current models of ADHD emphasize dysfunction within prefrontal cortical (PFC) networks responsible for executive control. These networks depend on precisely regulated catecholaminergic signaling, particularly involving dopamine and norepinephrine (Arnsten, 2011).

Importantly, this relationship follows an inverted U-shaped pattern, meaning that both insufficient and excessive catecholamine levels may impair PFC function. This highlights that simply increasing neurotransmitter levels does not necessarily lead to improved cognitive performance.

At the cellular level, intracellular signaling pathways—especially those involving cyclic adenosine monophosphate (cAMP)—play a key role. Elevated cAMP activity promotes the opening of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which weakens synaptic connectivity and disrupts sustained neuronal firing (Wang et al., 2007).

3. Mechanism of Action of Guanfacine

Guanfacine is a selective agonist of postsynaptic α2A-adrenergic receptors in the PFC. Activation of these receptors inhibits cAMP signaling and promotes closure of HCN channels, thereby strengthening synaptic connectivity and improving network stability (Wang et al., 2007).

Unlike psychostimulants, which broadly increase catecholamine availability, guanfacine acts in a more targeted way by modulating intracellular signaling within prefrontal circuits.

This mechanism likely enhances the signal-to-noise ratio within prefrontal cortical networks, allowing for more stable maintenance of task-relevant information. In practical terms, this may translate into improvements in working memory, inhibitory control, and sustained attention.

These mechanisms appear to be conserved across species, supporting their translational relevance (Arnsten, 2020). Moreover, guanfacine's selectivity for α2A receptors is thought to contribute to its relatively favorable tolerability profile compared to less selective agents such as clonidine (Neuchat et al., 2023).

4. Methodology

This narrative review was conducted to integrate mechanistic and clinically relevant evidence regarding the use of guanfacine in ADHD. A structured literature search was conducted using PubMed, Scopus, and Web of Science, covering publications from 2000 to 2024.

Search terms included combinations of "ADHD", "guanfacine", "alpha-2 agonists", "prefrontal cortex", and "non-stimulant treatment". Priority was given to randomized controlled trials, meta-analyses, systematic reviews, and key neurobiological studies.

Studies were included if they were randomized controlled trials, meta-analyses, systematic reviews, or key mechanistic studies directly addressing the use of guanfacine in ADHD. Case reports and non-English publications were excluded. The aim of this review was not to provide an exhaustive systematic synthesis, but rather a focused and clinically meaningful overview of the available evidence. As this was a narrative review, no formal risk-of-bias assessment was performed; however, priority was given to high-quality evidence, including randomized controlled trials and meta-analyses.

5. Results

The available literature consistently shows that guanfacine reduces core symptoms of ADHD, with the strongest evidence observed in pediatric populations. Randomized controlled trials and meta-analyses demonstrate statistically significant improvements compared to placebo, with moderate effect sizes reported across multiple randomized controlled trials and meta-analyses, and long-term studies suggest that these effects are sustained over time.

Across studies, effect sizes are generally smaller than those observed with psychostimulants, with standardized mean differences typically around 0.5–0.6 for guanfacine compared to approximately 0.8–1.0 for stimulant medications (Cortese et al., 2018). Some findings suggest that guanfacine may have a stronger impact on hyperactivity and impulsivity than on inattention, although results are not entirely consistent.

There is also evidence that guanfacine can be beneficial as adjunctive therapy. When combined with psychostimulants, it may improve overall treatment response, particularly in patients who do not achieve sufficient benefit from monotherapy.

In terms of safety, guanfacine is generally well tolerated. The most commonly reported adverse effects include sedation, fatigue, and hypotension.

Table 1. Key clinical trials of guanfacine in ADHD

Study	Population	Design	Main findings
Biederman et al., 2008	Children/adolescents	RCT	Significant symptom reduction vs placebo
Sallee et al., 2009	Children/adolescents	RCT	Improved ADHD-RS scores
Hervas et al., 2014	Pediatric	Phase III RCT	Confirmed efficacy and safety
Huss et al., 2018	Pediatric	Long-term study	Sustained efficacy
Iwanami et al., 2020	Adults	RCT	Modest but significant improvement

6. Clinical Efficacy

6.1. Pediatric population

Randomized controlled trials in children and adolescents consistently demonstrate reductions in ADHD symptom severity compared to placebo (Biederman et al., 2008; Sallee et al., 2009). Phase III studies further support both efficacy and safety (Hervas et al., 2014), and long-term data indicate sustained benefits (Huss et al., 2018).

6.2. Adult population

Evidence in adults is more limited. Available randomized trials suggest that guanfacine can reduce ADHD symptoms; however, effect sizes tend to be modest (Iwanami et al., 2020). Meta-analyses indicate that non-stimulant treatments, including guanfacine, are generally less effective than psychostimulants in adult populations (Cunill et al., 2016; Faraone & Glatt, 2010).

6.3. Adjunctive therapy

Guanfacine appears particularly useful as adjunctive therapy. Clinical studies suggest that its combination with psychostimulants may improve outcomes in patients with partial response to monotherapy (McCracken et al., 2016). Additional data support both the safety and efficacy of such combinations (Spencer et al., 2009; Wilens et al., 2012), especially with regard to impulsivity and emotional regulation.

7. Evidence from Meta-Analyses

Meta-analyses consistently demonstrate that guanfacine is more effective than placebo in reducing ADHD symptoms (Ruggiero et al., 2014; Yu et al., 2023). However, its effect size remains smaller than that observed with psychostimulants (Cortese et al., 2018).

Some evidence suggests that α2-agonists may be more effective for hyperactivity and impulsivity than for inattention, although findings remain heterogeneous (Hirota et al., 2014).

8. Safety and Tolerability

Guanfacine is generally well tolerated. The most frequently reported adverse effects include sedation, fatigue, and hypotension (Bello, 2015). These effects are usually dose-dependent and tend to decrease over time.

Compared to clonidine, guanfacine is associated with lower rates of sedation, which is likely related to its greater receptor selectivity (Neuchat et al., 2023).

9. Discussion

Guanfacine occupies a distinct position within ADHD pharmacotherapy due to its targeted effects on prefrontal cortical networks. In contrast to psychostimulants, which increase catecholamine levels more broadly, guanfacine acts at the level of intracellular signaling, thereby supporting the functional stability of executive control circuits.

Although its efficacy is generally lower than that of psychostimulants, guanfacine still provides clinically meaningful benefits. It is not typically considered a first-line monotherapy in most patients; however, it can play an important role in individualized treatment strategies. This is particularly evident in clinical practice, where guanfacine is often used in patients who do not fully respond to or tolerate stimulant medications.

When compared with other non-stimulant treatments, guanfacine shows a distinct clinical profile. Atomoxetine may have broader effects on attentional symptoms but often requires a longer time to achieve full efficacy, typically several weeks, whereas guanfacine may demonstrate earlier improvements in behavioral regulation, particularly in hyperactivity and impulsivity. Clonidine, due to its lower receptor selectivity, is associated with greater sedation and hypotension. In contrast, guanfacine may be especially helpful in addressing impulsivity and emotional dysregulation.

However, further research is still needed to better define its optimal place within treatment algorithms, particularly in adult populations.

Despite its demonstrated efficacy, several limitations should be considered. The variability in treatment response across studies suggests that guanfacine may be more effective in specific subgroups of patients, although these predictors are not yet well defined. Additionally, adverse effects such as sedation may impact adherence in clinical practice, particularly during the initial phase of treatment. Furthermore, the majority of available evidence is derived from controlled trial settings, which may not fully reflect real-world outcomes.

These findings support the growing role of mechanism-based, individualized pharmacotherapy in ADHD, where treatment selection is guided not only by symptom severity but also by underlying neurobiological profiles and tolerability considerations.

10. Limitations and Future Directions

Evidence in adults remains relatively limited, and direct head-to-head comparisons with other non-stimulant medications are scarce. Additionally, variability in study design and outcome measures makes interpretation more challenging.

It should also be noted that a number of randomized trials were industry-sponsored, which may influence reported outcomes. Future research should focus on long-term effectiveness, comparative studies, and identification of predictors of treatment response.

11. Clinical Implications

Guanfacine may be particularly beneficial in selected clinical scenarios, including:

- partial response to psychostimulants
- predominance of hyperactivity and impulsivity
- emotional dysregulation
- comorbid sleep disturbances
- presence of tic disorders or anxiety
- intolerance or contraindications to psychostimulants

In such cases, it may be used either as monotherapy or as part of combination treatment.

Guanfacine is typically administered once daily in an extended-release formulation, with doses ranging from 1 to 4 mg per day. Clinical effects may become evident within the first few weeks of treatment, although optimal response often requires gradual dose titration.

12. Conclusions

Overall, guanfacine represents a valuable non-stimulant option in the treatment of ADHD, supported by a well-established neurobiological rationale.

Although it does not achieve the same level of efficacy as psychostimulants, it offers meaningful clinical benefits and plays an important role in individualized treatment approaches, particularly in patients with specific clinical needs or treatment limitations.

Funding: No external funding was received for this study.

Conflicts of Interest: The author declares no conflicts of interest related to this work.

Author Contributions: The author was responsible for the conceptualization, literature review, writing, and editing of the manuscript.

REFERENCES

1. Arnsten, A. F. T. (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. *Biological Psychiatry, 69*(12), e89–e99. https://doi.org/10.1016/j.biopsych.2011.01.027
2. Arnsten, A. F. T. (2020). Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species. *Neurobiology of Learning and Memory, 176*, 107327. https://doi.org/10.1016/j.nlm.2020.107327
3. Banaschewski, T., Becker, K., Döpfner, M., Holtmann, M., Rösler, M., & Romanos, M. (2017). Attention-deficit/hyperactivity disorder. *Deutsches Ärzteblatt International, 114*(9), 149–159. https://doi.org/10.3238/arztebl.2017.0149
4. Bello, N. T. (2015). Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. *Patient Preference and Adherence, 9*, 877–885. https://doi.org/10.2147/PPA.S73167
5. Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., & Scherer, N. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics, 121*(1), e73–e84. https://doi.org/10.1542/peds.2006-3695
6. Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. *The Lancet Psychiatry, 5*(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
7. Cunill, R., Castells, X., Tobias, A., & Capella, D. (2016). Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: A meta-analysis and meta-regression in over 9000 patients. *Psychopharmacology, 233*(2), 187–197. https://doi.org/10.1007/s00213-015-4099-3
8. Faraone, S. V., & Glatt, S. J. (2010). A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *The Journal of Clinical Psychiatry, 71*(6), 754–763. https://doi.org/10.4088/JCP.08m04902pur
9. Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015). Attention-deficit/hyperactivity disorder. *Nature Reviews Disease Primers, 1*, 15020. https://doi.org/10.1038/nrdp.2015.20
10. Hervas, A., Huss, M., Johnson, M., McNicholas, F., van Stralen, J., Sreckovic, S., Lyne, A., Bloomfield, R., Sikirica, V., & Robertson, B. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, phase III trial. *European Neuropsychopharmacology, 24*(12), 1861–1872. https://doi.org/10.1016/j.euroneuro.2014.09.014
11. Hirota, T., Schwartz, S., & Correll, C. U. (2014). Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: A systematic review and meta-analysis. *Journal of the American Academy of Child & Adolescent Psychiatry, 53*(2), 153–173. https://doi.org/10.1016/j.jaac.2013.11.009
12. Huss, M., Chen, W., & Ludolph, A. G. (2016). Guanfacine extended release: A new pharmacological treatment option in Europe. *Clinical Drug Investigation, 36*(1), 1–25. https://doi.org/10.1007/s40261-015-0336-0
13. Huss, M., Dirks, B., Gu, J., Robertson, B., Newcorn, J. H., & Ramos-Quiroga, J. A. (2018). Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. *European Child & Adolescent Psychiatry, 27*(10), 1283–1294. https://doi.org/10.1007/s00787-018-1113-4
14. Iwanami, A., Saito, K., Fujiwara, M., Okutsu, D., & Ichikawa, H. (2020). Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study. *The Journal of Clinical Psychiatry, 81*(3), 19m12979. https://doi.org/10.4088/JCP.19m12979
15. Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., Spencer, T., Ustun, T. B., Walters, E. E., & Zaslavsky, A. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. *The American Journal of Psychiatry, 163*(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716
16. McCracken, J. T., McGough, J. J., Loo, S. K., Levitt, J., Del'Homme, M., Cowen, J., Sturm, A., Whelan, F., Hellemann, G., Sugar, C., & Bilder, R. M. (2016). Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: A controlled, comparative study. *Journal of the American Academy of Child & Adolescent Psychiatry, 55*(8), 657–666. https://doi.org/10.1016/j.jaac.2016.05.015
17. Neuchat, E. E., Bocklud, B. E., Kingsley, K., Barham, W. T., Luther, P. M., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023). The role of alpha-2 agonists for attention deficit hyperactivity disorder in children: A review. *Neurology International, 15*(2), 697–707. https://doi.org/10.3390/neurolint15020043
18. Newcorn, J. H., Stein, M. A., Childress, A. C., Youcha, S., White, C., Enright, G., & Rubin, J. (2013). Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: Morning or evening administration. *Journal of the American Academy of Child & Adolescent Psychiatry, 52*(9), 921–930. https://doi.org/10.1016/j.jaac.2013.06.006

19. Ota, T., Yamamuro, K., Okazaki, K., & Kishimoto, T. (2021). Evaluating guanfacine hydrochloride in the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients: Design, development and place in therapy. *Drug Design, Development and Therapy, 15*, 1413–1425. https://doi.org/10.2147/DDDT.S221126
20. Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. *International Journal of Epidemiology, 43*(2), 434–442. https://doi.org/10.1093/ije/dyt261
21. Raman, S. R., Man, K. K. C., Bahmanyar, S., Bilder, S., Boukhris, T., Bushnell, G., Crystal, S., Furu, K., KaoYang, Y.-H., Karlstad, Ø., Kieler, H., Kubota, K., Lai, E. C.-C., Martikainen, J. E., Maura, G., Moore, N., Montero, D., Nakamura, H., Neumann, A., Pate, V., Pottegård, A., Pratt, N. L., Roughead, E. E., Macias Saint-Gerons, D., Stürmer, T., Su, C.-C., Zoega, H., Sturkenboom, M. C. J. M., Chan, E. W., Coghill, D., Ip, P., & Wong, I. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. *The Lancet Psychiatry, 5*(10), 824–835. https://doi.org/10.1016/S2215-0366(18)30293-1
22. Ruggiero, S., Clavenna, A., Reale, L., Capuano, A., Rossi, F., & Bonati, M. (2014). Guanfacine for attention deficit and hyperactivity disorder in pediatrics: A systematic review and meta-analysis. *European Neuropsychopharmacology, 24*(10), 1578–1590. https://doi.org/10.1016/j.euroneuro.2014.08.001
23. Sallee, F. R., McGough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 48*(2), 155–165. https://doi.org/10.1097/CHI.0b013e318191769e
24. Sibley, M. H., Mitchell, J. T., & Becker, S. P. (2016). Method of adult diagnosis influences estimated persistence of childhood ADHD: A systematic review of longitudinal studies. *The Lancet Psychiatry, 3*(12), 1157–1165. https://doi.org/10.1016/S2215-0366(16)30190-0
25. Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009). Prevalence and correlates of adult attention-deficit/hyperactivity disorder: Meta-analysis. *The British Journal of Psychiatry, 194*(3), 204–211. https://doi.org/10.1192/bjp.bp.107.048827
26. Spencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009). Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with ADHD. *Journal of Child and Adolescent Psychopharmacology, 19*(5), 501–510. https://doi.org/10.1089/cap.2008.0152
27. Taylor, F. B., & Russo, J. (2001). Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. *Journal of Clinical Psychopharmacology, 21*(2), 223–228. https://doi.org/10.1097/00004714-200104000-00015
28. Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., Mazer, J. A., McCormick, D. A., & Arnsten, A. F. T. (2007). α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. *Cell, 129*(2), 397–410. https://doi.org/10.1016/j.cell.2007.03.015
29. Wilens, T. E., Bukstein, O., Brams, M., Cutler, A. J., Childress, A., Rugino, T., Lyne, A., Grannis, K., & Youcha, S. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry, 51*(1), 74–85. https://doi.org/10.1016/j.jaac.2011.10.012
30. Willcutt, E. G. (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. *Neurotherapeutics, 9*(3), 490–499. https://doi.org/10.1007/s13311-012-0135-8
31. Yu, S., Shen, S., & Tao, M. (2023). Guanfacine for the treatment of attention-deficit hyperactivity disorder: An updated systematic review and meta-analysis. *Journal of Child and Adolescent Psychopharmacology*. https://doi.org/10.1089/cap.2022.0038